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InXammatory disorders of the pituitary comprise a noso-
logically heterogenous group of lesions, the wide spectrum
of which actually belies the perceived rarity of individual
entities. These range from “bystander” involvement by
inXammation of adjacent skull base or meninges (second-
ary hypophysitis), to self-perpetuating reparative lesions
(sellar xanthogranuloma), to mononuclear inWltrates that
can involve the pituitary either primarily or as part of sys-
temic autoimmune disease [7, 9, 10].
Among the latter, lymphocytic hypophysitis (LYH)
stands out as the single most important lesion, both
because of its relative frequency and complex diVerential
diagnosis [3, 7]. LYH tends to come to attention by vir-
tue of its local tissue destruction or space-occupying
character. While virtually every combination of site-
speciWc clinical symptoms may result, hyperprolactin-
emia—especially one referable to “stalk section eVect”—
may occasionally occur as well [7].
In the context of ongoing or recently completed preg-
nancy, and more generally female gender and reproduc-
tive age, LYH has been notorious for often being nearly
indistinguishable—if thought of at all—from prolacti-
noma, on clinical grounds. Histological conWrmation of
either diagnosis has been regarded as one excluding its
alternative counterpart, for there is no reference in the
literature to any case of pituitary harboring both prolac-
tinoma and lymphocytic inXammation.
We recently had the privilege of studying an adenom-
ectomy specimen with concurrent prolactinoma and con-
spicuous intratumoral inWltration by reactive lymphocytes.
The patient, a 31-year-old nulliparous woman, underwent
transsphenoidal microsurgery for oligo-amenorrhea with
laboratory evidence of moderate hyperprolactinemia
(140 g/l). No preoperative dopaminergic therapy was
attempted. The referring physician negated any clinical
evidence of coexistent systemic inXammatory or autoim-
mune disease. Magnetic resonance imaging (MRI) showed
a macroadenoma of 12 mm in diameter with intact sellar
contours (Fig. 1a, b).
A fairly generous surgical specimen of 1.2 £ 1 £ 0.3 cm
was available for processing, complete with some well-
preserved residues of nontumorous adenohypophysis as
well as small fragments of posterior lobe. The neoplastic
moiety consisted of a slightly basophilic prolactin cell
adenoma (WHO grade I) with monotypic expression of
prolactin (PRL) in a Golgi-bound pattern, as well as
robust CAM 5.2 (for cytokeratin 8 and cytokeratin 18)
positivity (Fig. 1d, e). In addition, multiple angiocentric
inWltrates of mononuclear cells were seen along intratu-
moral vascular septa (Fig. 1c). These comprised mostly
CD3+ T lymphocytes, among which CD4+ helper cells
predominated over those of CD8+ suppressor phenotype
(Fig. 1f, h). Cytotoxic T cells featuring Granzyme-B or
TIA-1 positive granules occurred very rarely (not shown).
There were lesser amounts of interspersed CD79a+ B
cells and only scarce CD68+ monocytes (Fig. 1i). Only
seldom did the latter assume macrophage morphology;
neither epithelioid cells nor granulomas were present.
Morphological evidence of cell destruction, especially
apoptotic Wgures or necrosis were absent, as was Wbrosis.
However, occasional CD68+ cells were seen intimately
engaged with minute clusters of MHC II (HLA-DR)
expressing adenoma cells via dendritic processes (Fig. 1j).
The inWltrate was felt to be conWned within intratumoral
boundaries, while the adjacent residual parenchyma
remained remarkably free of any inXammatory cells
(Fig. 1k, l).
Our review of the literature yielded a mere two speciWc
references to simultaneous neoplastic and inXammatory
pathologies of the pituitary. The case reported by Holck
and Laursen [4] involved a prolactinoma coexisting with
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398and indeed inWltrated by granulomatous hypophysitis.
The authors’ discussion is mainly focused on potential
analogies between diVerent forms of granulomatous reac-
tion in endocrine organs. This article does not provide
subtyping of inXammatory cells. In a second publication
by McConnon et al. [8], a sparsely granulated somato-
troph cell adenoma in the context of otherwise classic
LYH is dealt with. The inXammatory inWltrate is
described as one focally impinging upon, rather than pri-
marily involving neoplastic tissue.
399The present case fulWlls morphologic criteria of cell-
mediated host immune reaction to bodily antigens, as
seen in both tumors and under non-neoplastic conditions,
including the pituitary [3]. This is unlikely to represent a
mere coincidence, since the nontumorous adenohypophy-
sis was remarkably exempt from inXammation. While
postulating host defense mounted against adenoma cells
readily comes to mind, diagnostic experience with pitui-
tary adenomas fails to provide supporting evidence to this
eVect. Although pituitary epithelial cells do secrete poten-
tial autoantigens—among them PRL—the intratumoral
microenvironment of adenomas seems to be lacking com-
petence for antigen presentation [2, 5]. Pituitary adenomas
have been shown not to depend on mitogenic signals con-
veyed by, and indeed tend to be devoid of folliculostellate
cells—ones capable of antigen presentation in the context
of MHC II molecules [1, 11]. To the best of our knowl-
edge, expression of the latter has not been systematically
investigated in pituitary adenomas. We document surface
expression of HLA-DR molecules in a small minority of
adenoma cells, ones consistently associated with CD68+
monocytes of dendritic morphology. Keeping in mind the
versatile immunomodulatory eVects of PRL, especially on
Th1 and Th2 lymphocytes in the early phase of inXamma-
tion, we propose that the lesion described here may reXect
a short-lived cell mediated response directed at a subpop-
ulation of tumor cells [2]. Whether proWcient in eliminat-
ing individual tumor cells or not, this process is possibly
ephemeral, and will eventually subside in the nonaccomo-
dating immunologic milieu of the tumor. Since most pro-
lactinomas only come to surgery after weeks to months of
unresponsiveness to medication with dopamine agonists,
this transitory phenomenon—should the present example
be more than just a fortuitous occurrence—is likely to be
missed [6].
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Fig. 1 a Sagittal post-Gadolinium MRI scan to show moderately
enhancing pituitary mass with minimal suprasellar extension, yet
unaVected bony contours. Slight displacement of pituitary stalk is
evident (empty arrow). b T2 weighted frontal scan reveals intratu-
moral hyperintensity as compared to displaced residual pituitary
parenchyma (solid arrow). Discreet outward kinking of pituitary
stalk is appreciated (empty arrow). c Histological overview of inXam-
matory prolactinoma to show otherwise unremarkable, slightly
basophilic adenoma tissue permeated by lymphocytes along vascu-
lar septa. d, e Tumor cells are identiWed as ones of lactotroph lineage
by coexpression of PRL and low molecular weight cytokeratin. Note
juxtanuclear Golgi-pattern of PRL immunoreactivity. f–i Perivascu-
lar area of tumor represented on serial sections to show cellular com-
position of inXammatory cuVs. Predominance of CD4+ T
lymphocytes is appreciated by comparing g and h. j Occasional
mononuclear elements with dendritic processes interact with small
clusters of adenoma cells displaying conspicuous surface expression
of MHC class II antigens. k, l Overview of adenoma/pituitary inter-
face to show sparing of nontumorous tissue (lower half) by the pro-
cess—which is quite pronounced in this Weld. Faint
immunoreactivity of adenoma cells for Chromogranin assists in
localizing transition zone. Slide in c was stained with hematoxylin
and eosin; d–l were developed with EnVision (DAKO®) using new
fuchsin as chromogen. Bars: c 120 m; d–i 40 m; j 32 m; k, l 80 m
